Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02180724 · ClinicalTrials.gov registry record · Phase 2

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

A Phase 2 study of Waldenström Macroglobulinemia (WM), sponsored by Acerta Pharma.

Active
Registry status
Phase 2
Development phase
107
Enrollment target
20
Study locations

NCT02180724: Active Phase 2 study of Waldenström Macroglobulinemia (WM), sponsored by Acerta Pharma.

NCT02180724 is a Phase 2 study of Waldenström Macroglobulinemia (WM) that is active but no longer recruiting, run by Acerta Pharma. The registered enrollment target is 107 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02180724, a Phase 2 study of Waldenström Macroglobulinemia (WM), is active but no longer recruiting, sponsored by Acerta Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
107 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.

Primary Outcome

ORR defined as the rate of subjects achieving a Miner Response (MR) or better including complete response (CR), very good partial response (VGPR), partial response (PR) and MR; The definition of responses are evaluated by investigators using both Modified 6th criteria (refer to protocol table 4-2 , 4-3) and Modified 3rd International Workshop of Waldenström Macroglobulinemia (IWWM) criteria (refer to protocol table 4-4 and table 4-5 for definition). For Modified 6th criteria, MR is defined as (1

Conditions Studied

Waldenström Macroglobulinemia (WM)

Interventions

  • DRUG Acalabrutinib (ACP-196)

Study Locations (20)

Other

  • Research Site - Aurillac
  • Research Site - Clermond Ferrand
  • Research Site - Marseille
  • Research Site - Montpellier
  • Research Site - Nantes
  • Research Site - Paris
  • Research Site - Paris
  • Research Site - Pierre-Bénite
  • Research Site - Poitiers
  • Research Site - Reims

Texas

  • Research Site - Austin
  • Research Site - Bedford
  • Research Site - Houston

California

  • Research Site - Santa Barbara

Colorado

  • Research Site - Aurora

District of Columbia

  • Research Site - Washington D.C.

Minnesota

  • Research Site - Minneapolis

New York

  • Research Site - New York

Tennessee

  • Research Site - Nashville

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2014-09-11
Est. Completion 2026-12-31
Phase Phase 2
Acerta Pharma

38 total trials

What the registry record for NCT02180724 still lists

NCT02180724 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).

The record links to 1 condition, with Waldenström Macroglobulinemia (WM) appearing as the primary indexed condition, and to 1 intervention - of which Acalabrutinib (ACP-196) is the first listed.

NCT02180724 names 20 study sites across 9 states, led by Other, Texas, California.

Frequently Asked Questions

What is clinical trial NCT02180724 about?

NCT02180724 is a clinical study titled "An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia". The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.

What is the current status of trial NCT02180724?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2014-09-11. Estimated completion is 2026-12-31.

What conditions does trial NCT02180724 study?

This clinical trial studies the following conditions: Waldenström Macroglobulinemia (WM).

What interventions are being tested in trial NCT02180724?

The interventions under investigation include: Acalabrutinib (ACP-196) (DRUG).

Who is sponsoring clinical trial NCT02180724?

This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02180724 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT02180724's enrollment target sits among peer trials

107 646th of 2000 higher than 1,353 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05491668 · 107 participants

    Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI

  • NCT06041594 · 107 participants · NA

    Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)

  • NCT06081426 · 107 participants · NA

    Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)

  • NCT06527599 · 107 participants · NA

    Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02180724, the US trial registry maintained by the National Library of Medicine. NCT02180724 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.